SALT LAKE CITY, Feb. 9, 2012 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on the development of small molecule therapeutics with novel chemical structures and distinct mechanisms of action, today reported financial results for its second fiscal quarter ended December 31, 2011.
